Morning Briefing
Summaries of health policy coverage from major news organizations
PrEP Raises Questions Regarding 'Risk Disinhibition' And Drug Resistance
Nature News reports on "the possibility of unintended public-health consequences" of pre-exposure prophylaxis (PrEP) for HIV and pharmaceutical company Gilead's plan to ask the FDA to evaluate its combination antiretroviral (ARV) drug Truvada for use in healthy people.
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
